Drug Treatment Study for Boys with Duchenne Muscular Dystrophy

The purpose of this study is to assess the safety and tolerability of an anti-myostatin adnectin called BMS-986089 in ambulatory boys with genetically confirmed Duchenne muscular dystrophy (DMD).

In order to participate you must meet the following criteria:

• Be male, 5 to 10 years old and ambulatory without assistance.
• Weigh at least 15 kg.
• Have a diagnosis of DMD, confirmed by genotyping.
• Are receiving corticosteroids (eg, prednisone, prednisolone, or deflazacort) for at least 6 months prior to the start of study drug administration.

You will be excluded from the study if any of the following criteria apply to you:

• Have a history of current renal disease.
• Have ejection fraction < 55% on screening echocardiogram.
• Have known cognitive impairment or behavioral issues that will compromise ability to comply with study procedure.
• Have uncontrolled clinical signs and symptoms of chronic heart failure (American College of Cardiology/American Heart Associated Stage C or D).

This is a partial list of inclusion and exclusion criteria.